« Back
Home /
Urolithin D

Urolithin D

Item no.	HY-133178-1ea
Manufacturer	MedChem Express
CASRN	131086-98-1
Amount	1 ea
Quantity options	100 mg 10 mM/1 mL 10 mg 1 ea 25 mg 50 mg 5 mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	99.72
Citations	[1]Giorgio C, et al. The ellagitannin colonic metabolite urolithin D selectively inhibits EphA2 phosphorylation in prostate cancer cells. Mol Nutr Food Res. 2015 Nov;59(11):2155-67. \|[2]Kang I, et al. Urolithin A, C, and D, but not iso-urolithin A and urolithin B, attenuate triglyceride accumulation in human cultures of adipocytes and hepatocytes. Mol Nutr Food Res. 2016 May;60(5):1129-38.\|[3]Milanović Ž. Urolithin D: A promising metabolite of ellagitannin in combatting oxidative stress. Chem Biol Interact. 2025 Apr 25;411:111444.
Smiles	O=C1C2=CC(O)=C(O)C=C2C3=CC=C(O)C(O)=C3O1
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	3,4,8,9-Tetrahydroxy urolithin
Shipping Condition	Room temperature
Available
Manufacturer - Type	Natural Products
Manufacturer - Applications	Cancer-Kinase/protease
Manufacturer - Targets	AMPK; Ephrin Receptor; PPAR
Shipping Temperature	Room Temperature
Storage Conditions	4°C (Powder, protect from light)
Molecular Weight	260.20
Product Description	Urolithin D (3, 4, 8, 9-Tetrahydroxy urolithin) is a colonic metabolite of Ellagitannins and a competitive, reversible, and selective antagonist of the EphA receptor. Urolithin D inhibits EphA2-ephrin-A1 binding with an IC50 of 0.9 μM. Urolithin D is also a potent antioxidant that scavenges free radicals and repairs oxidized DNA damage. Additionally, Urolithin D suppresses triglyceride accumulation and promotes fatty acid oxidation by activating the AMPK signaling pathway. Urolithin D can be used for research on tumors, metabolic, and inflammatory diseases[1][2][3].
Manufacturer - Research Area	Cancer; Metabolic Disease; Inflammation/Immunology
Solubility	DMSO: 125 mg/mL (ultrasonic)
Manufacturer - Pathway	Cell Cycle/DNA Damage; Epigenetics; Metabolic Enzyme/Protease; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK; Vitamin D Related/Nuclear Receptor
Isoform	EphA; PPARγ
Clinical information	No Development Reported

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-133178-1ea-safety-datasheet.pdf